Lead Product(s) : oNKord,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : oNKord (allogeneic ex vivo-generated NK cells) is immunotherapy product in clinical development. It gets produced in a closed system in Glycostem’s state-of-the-art and GMP licensed production facility, from which it can be distributed globally.
Product Name : oNKord
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : oNKord,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : oNKord,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : medac
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® (GTA002) in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients.
Product Name : oNKord
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 08, 2022
Lead Product(s) : oNKord,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : medac
Deal Size : Undisclosed
Deal Type : Licensing Agreement
FDA Grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma
Details : ONKord® is Glycostem’s first-generation off-the-shelf Natural Killer (NK) cellular immunotherapy product. Over the coming months, AML patients will receive this form of treatment as part of a phase I-IIa (pivotal) trial in AML.
Product Name : oNKord
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 10, 2020
Lead Product(s) : oNKord,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : WiNK is a two-stage phase I/IIa trial to study the safety and efficacy of oNKord®, an off-the-shelf, ex. vivo-cultured allogeneic NK cell preparation, AML patients who are in complete morphologic remission with no strong indication for hematopoietic ste...
Product Name : oNKord
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 20, 2020
Lead Product(s) : oNKord,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclophosphamide,Fludarabine Phosphate,Allogeneic Ex Vivo-Generated NK Cell
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Cyclophosphamide,Fludarabine Phosphate,Allogeneic Ex Vivo-Generated NK Cell
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Lumicks
Deal Size : Undisclosed
Deal Type : Collaboration
LUMICKS Enters Collaboration with Glycostem to Enhance NK cell-Mediated Immunotherapy
Details : Glycostem will assess their NK cells using LUMICKS’ z-Movi to gain new insights into the cell avidity and functional properties of their cells. Avidity is a new parameter that is crucial to understand immune cells better and choose the most potent ones...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Lumicks
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
